Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said
You may also be interested in...
Perrigo Licenses Antihistamine Levocetirizine, “Prime” Switch Candidate
Perrigo's licensing agreement with Synthon Pharmaceuticals to market a generic of UCB's antihistamine Xyzal brings the private labeler a "prime example" of an Rx-to-OTC switch candidate. Switch is a "likely scenario" for the allergy drug, Perrigo maintains
Zyrtec Launch Brings Big Boost To Johnson & Johnson, But Competition Grows
Johnson & Johnson's OTC sales jumped 27 percent to $1.6 billion in the firm's first earnings period with allergy medication Zyrtec (cetirizine 5 mg) available over the counter, according to J&J
Children’s Claritin Ad Stresses Safety In Wake Of Cough/Cold Advisory
Schering-Plough's latest television ad for Children's Claritin capitalizes on recent safety concerns about products in the pediatric OTC cough/cold monograph